Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

23:17 EDT 22 Aug 2017 | ChinaBio Today

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at severe acute pancreatitis. Samsung Biologics has two divisions: a biologics CMO operation, and Samsung Bioepis, a company formed by Samsung and Biogen. Until now, Bioepis has been developing biosimilars, but the Takeda agreement will take Bioepis into novel drug development for the first time. One year ago, Samsung Biologics staged a $2 billion IPO on the Korean market. More details....

Stock Symbols: (KS: 207940) (TYO: 4502) (NSDQ: BIIB)

Share this with colleagues:

Original Article: Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma


More From BioPortfolio on "Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...